All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
JZP458 in ALL/LBL: Complete follow-up results from AALL1931 trial
Bookmark this article
|
The phase II/III ALL1931 trial (NCT04145531) assessed the efficacy and safety of JZP458, a recombinant Erwinia asparaginase, in children and adult patients with ALL or LBL who had developed sensitivity to Escherichia coli-derived asparaginases. The ALL Hub previously reported the primary results and post-hoc analysis results from this trial. Recently, the complete follow-up results from the trial were published in Blood Advances by Maese. The study evaluated the efficacy and safety of different doses of JZP458 administered MWF in 2 cohorts (IM and IV). The primary efficacy endpoint was safety and the proportion of patients achieving NSAA level of ≥0.1 IU/mL in the last 72 hours during Course 1 of IM JZP458.1 |
| Key learnings |
| The proportion of patients reaching the NSAA level of ≥0.1 IU/mL in the last 72 hours was 64% in the IM 25 mg/m², 91% in the IM 37.5 mg/m², 90% in the IM 25/25/50 mg/m² cohort, and 40% in the IV 25/25/50 mg/m² cohort. |
| The frequency of serious TRAEs was 29% and 48% in the IM and IV cohorts, respectively. |
| Treatment discontinuation was reported in the 23% and 56% of patients in the IM and IV cohorts due to TRAEs (mainly allergic reactions and pancreatitis). |
| The complete follow-up results from the ALL1931 trial support the use of JZP458 in patients with ALL/LBL who are hypersensitive to Escherichia coli-derived asparaginases. |
Abbreviations: ALL, acute lymphoblastic leukemia; IM intramuscular; IV, intravenous; LBL, lymphoblastic lymphoma; MWF, Monday/Wednesday/Friday; NSAA, nadir serum asparaginase activity; TRAE, treatment-related adverse event.
- Maese LD, Loh ML, Agarwal MR, et al. Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete follow-up of the children's oncology group AALL1931 study. Blood Adv. Online ahead of print. DOI: 10.1182/bloodadvances.2024013346
More about...
Your opinion matters
6 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox